Malignant Soft Tissue Sarcoma Clinical Trial
Official title:
The Use of Propranolol Hydrochloride Combined With Anthracyclin Based Chemotherapy in the Treatment of Metastatic Soft Tissue Sarcoma
Fifty patients with pathological proof of malignant soft tissue sarcoma will receive
Anthracyclin based chemotherapy combined with propranolol 40 mg twice daily.
- The primary end point : To assess Progression Free Survival (PFS)
- The secondary end points : To assess Overall Survival (OS) and Toxicity Profile
n/a